Innate Pharma SA (IPHA) stock

IPHANasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31Also trades as IPHYF

Financials through fiscal 2025, year ended Dec 31, 2025Last filing: 20-F on Apr 1, 2026Score 0/30

$1.49−0.10 (-6.29%)

Close on Nov 12, 2026Market cap $139.64MP/E –Yield –

Innate Pharma price to sales ratio

The price-to-sales ratio is market cap divided by revenue over the trailing twelve months.

Innate Pharma's price to sales ratio was 14.2× on Nov 11, 2026, against 6.8× a year earlier. Over the last 5 years it ranged from 1.9× to 18.6×, with a median of 6.2×.

Price to Sales Ratio at the end of each year

Period	Period end	Value	Change (pts)
2026	Nov 11, 2026	14.2×	+8.2
2025	Dec 31, 2025	6.0×	+3.7
2024	Dec 31, 2024	2.3×	−1.2
2023	Dec 29, 2023	3.5×	−7.7
2022	Dec 30, 2022	11.2×	+6.7
2021	Dec 31, 2021	4.6×	+1.9
2020	Dec 31, 2020	2.6×	−1.0
2019	Dec 31, 2019	3.6×	–

Where these numbers come from

Parsed from the XBRL in Innate Pharma's annual and quarterly filings with the SEC
Fourth quarters derived from the annual report minus nine months
Every figure in the statements links to its source filing

Against peers

Trailing twelve months. Peers are matched on business description, industry and size. Ticks are peers, the dot is IPHA.

Compare: IPHA vs MOLN · IPHA vs TCRX · IPHA vs EVAX · IPHA vs CRBU · IPHA vs CRIS

Revenue growth-55.2% · median -38.4%

Operating margin-599.8% · median -1140.6%

Company	Revenue	Growth
CRBU	$9.44M	+1.6%
IPHA	€9.01M	-55.2%
TCRX	$5.19M	-38.4%
CRIS	$4.31M	-62.2%
MOLN	–	–
EVAX	–	–

Company

Exchange: Nasdaq
Industry: Biological Products, (No Diagnostic Substances)
Fiscal year ends: December 31
Employees: 181
Auditor: Deloitte & Associes
SEC CIK: 1598599

Advertisement
300 × 250

See a number that looks wrong?

Innate Pharma price to sales ratio

Price to Sales Ratio at the end of each year

More Innate Pharma figures